Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival

Lynch, GS; Anderton, H; Silke, J; Laine, D; Casey, JL; Tanzer, M; Schloegel, J; Sahay, T; Dillon, H; Weston, R; Liu, SY; Wong, WW; Talbo, G; Schneider, P; Scott, AM; Hoogenraad, J; Gregorevic, P; Foley, M; Jayatilleke, KM; Johnston, AJ; Faou, P; Emmrich, K; Hoogenraad, NJ; Levina, V; Burkly, LC; Jenkinson, L; Murphy, KT; Hall, C
Abstract
The cytokine TWEAK and its cognate receptor Fn14 are members of the TNF/TNFR superfamily and are upregulated in tumors. We found that Fn14, when expressed in tumors, causes cachexia and that antibodies against Fn14 dramatically extended lifespan by inhibiting tumor-induced weight loss although having only moderate inhibitory effects on tumor growth. Anti-Fn14 antibodies prevented tumor-induced inflammation and loss of fat and muscle mass. Fn14 signaling in the tumor, rather than host, is responsible for inducing this cachexia because tumors in Fn14- and TWEAK-deficient hosts developed cachexia that was comparable to that of wild-type mice. These results extend the role of Fn14 in wound repair and muscle development to involvement in the etiology of cachexia and indicate that Fn14 antibodies may be a promising approach to treat cachexia, thereby extending lifespan and improving quality of life for cancer patients. Copyright © 2015 Elsevier Inc. All rights reserved.
Journal CELL
ISSN 0092-8674
Published 10 Sep 2015
Volume 162
Issue 6
Pages 1365-78
DOI 10.1016/j.cell.2015.08.031
Type Journal Article
Sponsorship
NHMRC